Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo sold 17,717 shares of common stock in open-market transactions on July 6, 2026 at a weighted average price of $18.69 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025, meaning the sales were scheduled in advance.
The sale was completed in multiple trades at prices ranging from $18.39 to $19.38 per share. After these transactions, Catinazzo directly owns 159,744 shares of Relay Therapeutics common stock, which includes 9,807 shares underlying restricted stock units.
Relay Therapeutics, Inc. reports a proposed sale by its director and officer Sanjiv Patel of 144,597 common shares, with an aggregate market value of $2,732,883.30 and an approximate sale date of July 7, 2026. The shares were acquired from the issuer as restricted stock units on February 10, 2025; the reported Rule 10b5-1 plan adoption or instruction date is October 30, 2025.
Relay Therapeutics, Inc. officer Peter Rahmer reported a sale of 50,000 shares of common stock on June 30, 2026 at a weighted average price of $19.09 per share, executed in multiple trades pursuant to a Rule 10b5-1 trading plan adopted on October 31, 2025. He also acquired 3,056 shares at $6.95 per share. After these transactions he directly holds 228,913 shares, including 9,153 shares underlying restricted stock units.
RLAY Section 144 notice reports intent related to 50,000 Performance Stock Units dated 01/29/2025 and discloses a recent sale of 753 Common shares on 04/28/2026 for $11,136.87. The filing lists Morgan Stanley Smith Barney LLC as the broker and includes a table row dated 06/30/2026.
Relay Therapeutics, Inc. reported that Chief Financial Officer Thomas Catinazzo exercised stock options and sold common shares in a series of same-day transactions. He exercised options for a total of 169,446 shares of common stock at exercise prices of $4.45, $5.22, and $5.04 per share. He then completed open-market sales totaling 187,163 shares at prices reported around $16.97–$17.01 per share, executed in multiple trades within disclosed price ranges. Following these transactions, he directly owned 177,461 shares of common stock, which include 9,807 shares underlying restricted stock units. The filing notes that at least one of the reported transactions was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025.
Relay Therapeutics, Inc. reported that President, R&D Donald A. Bergstrom exercised options for 93,456 shares of common stock at $4.12 per share and sold 93,456 shares at a weighted average price of $16.94 per share in multiple trades ranging from $16.15 to $17.39, pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025.
After these transactions, he directly holds 418,557 shares of common stock, including 15,037 shares underlying restricted stock units. The exercised option, which was fully vested and had an expiration date of April 9, 2028, now has no remaining balance.
Relay Therapeutics, Inc. (RLAY) officer Donald Bergstrom reported a proposed sale of 110,646 common shares, with an aggregate market value of $1,757,058.48 and an approximate sale date of June 22, 2026. The notice lists October 30, 2025 as the plan adoption or instruction date if relying on Rule 10b5-1.
Relay Therapeutics, Inc. officer Thomas Catinazzo reported a proposed sale of 204,880 common shares, with an approximate sale date of June 22, 2026, and an aggregate market value of $3,253,494.40. The notice names Morgan Stanley Smith Barney LLC as broker and reports 191,586,165 common shares outstanding.
The past-sales section lists four sales: 17,717 shares for $227,808.73 on May 14, 2026; 972 shares for $14,375.88 on April 28, 2026; 1,800 shares for $27,000.00 on April 9, 2026; and 17,717 shares for $230,577.90 on April 7, 2026. Three entries are labeled 10b5-1 sales. The stated date of plan adoption or giving of instruction, if relying on Rule 10b5-1, is October 30, 2025.
Relay Therapeutics director Claire Mazumdar received a new stock option grant. The Form 4 reports an award of options covering 32,947 shares of Relay Therapeutics common stock at an exercise price of $14.09 per share. These options vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that date and expire on June 8, 2036. After this grant, Mazumdar holds stock options for 32,947 underlying shares directly.
Relay Therapeutics director Habib J. Dable received a new stock option award covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and expires on June 8, 2036. It vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the company’s next annual stockholder meeting. Following this grant, Dable holds options covering 32,947 underlying shares directly.